Merck 2025 Q3 Earnings Strong Performance as Net Income Surges 83.1%

Merck (MRK) reported Q3 2025 earnings that exceeded expectations, with revenue rising 3.7% to $17.28 billion and EPS surging 85.8% to $2.32. The company raised full-year revenue guidance to $72.5–74.5 billion, reflecting strong demand for Keytruda and cost efficiencies. Despite a 3.8% stock price jump post-earnings, shares underperformed the S&P 500 year-to-date, as analysts highlighted risks from Keytruda’s patent cliff and Gardasil’s 25% sales decline.

Revenue

Merck’s Q3 revenue totaled $17.28 billion, a 3.7% increase from $16.66 billion in the prior year. The pharmaceutical segment led growth, generating $15.61 billion, driven by Keytruda’s $8.14 billion in sales—a 8% year-over-year increase. Gardasil sales, however, fell 25% to $1.75 billion due to China demand challenges. Hospital Acute Care contributed $829 million, while Cardiovascular revenue reached $554 million. Vaccines revenue declined modestly to $3.15 billion, with Vaxneuvance and RotaTeq offsetting some Gardasil losses. Animal Health added $1.61 billion, with Livestock and Companion Animal segments performing steadily.

Earnings/Net Income

Merck’s net income soared 83.1% to $5.79 billion in Q3 2025, with EPS rising to $2.32 from $1.25 in the prior year. The 30.36% net margin reflects disciplined cost management and a favorable product mix. The 83.1% net income growth and 85.8% EPS increase reflect robust operational performance and strategic cost management, marking a record high for Q3 net income in over two decades.

Post-Earnings Price Action Review

Merck’s stock surged 3.8% immediately after the Q3 earnings report, but shares retreated 1.73% over the subsequent week and fell 4.60% month-to-date. Analysts remain cautious, citing near-term risks such as Keytruda’s looming patent expiration in 2028 and ongoing Gardasil sales headwinds. While the earnings beat demonstrated short-term momentum, long-term growth depends on mitigating competitive pressures and executing on R&D investments like the Verona Pharma acquisition.

CEO Commentary

Merck’s CEO, Robert M. Davis, emphasized resilience in oncology and hospital generic businesses, stating, “Our focus on innovation in high-margin segments will strengthen long-term market positioning.” He acknowledged near-term challenges, including supply chain disruptions and regulatory delays, but expressed confidence in the portfolio’s ability to adapt.

Guidance

Merck provided full-year 2025 guidance of $72.5–74.5 billion in revenue and $9.20–9.60 in EPS, reflecting current trends and R&D progress. The company plans $2.1–2.3 billion in CAPEX to expand manufacturing capabilities and aims to maintain a mid-single-digit operating margin.

Additional News

Merck’s recent acquisition of Verona Pharma underscores its strategy to diversify its pipeline, with the deal offering multi-billion-dollar commercial potential. Institutional investors, including Amplius Wealth Advisors, increased holdings by 117.4% in Q2, while Retirement Systems of Alabama sold 4,775 shares. Analyst sentiment remains mixed, with Morgan Stanley and Berenberg Bank downgrading the stock to “Hold” due to patent risks and competitive pressures.

<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-aime_generated_1761964510528.jpg.png" style="max-width:100%;">